Paper Details

  1. Home
  2. Paper Details

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Author: AlojLuigi, ArenareLaura, AvalloneAntonio, BilanciaDomenico, BottiGerardo, BudillonAlfredo, CarlomagnoChiara, CassataAntonino, De StefanoAlfonso, DelrioPaolo, Di GennaroElena, GalloCiro, GranataVincenza, IzzoFrancesco, LastoriaSecondo, LeoneAlessandra, NappiAnna, NastiGuglielmo, PerroneFranco, PetrilloAntonella, PiccirilloMaria C, RomanoCarmela, RosatiGerardo, SilvestroLucrezia, TatangeloFabiana, VicarioValeria

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sequential administration of bevacizumab plus chemotherapy did not improve objective response rate (ORR) in patients with metastatic colorectal cancer (mCRC). However, it led to improved overall survival, fewer adverse effects, and better quality of life.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Although bevacizumab is a standard of care in combination treatments for metastatic colorectal cancer (mCRC), its clinical benefit has been limited. OBJECTIVE: To determine whether sequential scheduling of bevacizumab administration in combination with chemotherapy improves treatment ef...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314140/

データ提供：米国国立医学図書館（NLM）

Bevacizumab in Combination with Chemotherapy for Metastatic Colorectal Cancer

This study explores the challenging landscape of [metastatic colorectal cancer (mCRC)], a condition that can be as daunting as navigating a vast and unforgiving desert. The researchers, like skilled desert explorers, investigate the potential of [bevacizumab] in combination with chemotherapy to combat this aggressive disease. They seek to find a path towards more effective treatment options and improved patient outcomes.

Sequential Bevacizumab Administration Shows Promise

The study found that [sequential administration of bevacizumab in combination with chemotherapy may offer an advantage in overall survival] for patients with mCRC. This is like discovering a hidden oasis in the desert that provides a crucial source of sustenance and hope for survival in the face of a harsh environment.

Potential for Improved Quality of Life

The researchers' findings suggest that [sequential bevacizumab administration could also improve quality of life] for patients with mCRC by reducing the severity of certain side effects. This is like finding a new and resilient species of plant that can thrive in the harsh desert environment, offering a beacon of hope for a better future.

Dr.Camel's Conclusion

This study sheds light on the potential benefits of sequential bevacizumab administration in combination with chemotherapy for metastatic colorectal cancer. The findings suggest that this approach may offer a more effective treatment strategy, potentially improving overall survival and quality of life for patients. This research is like a treasure map guiding us towards a more informed approach to managing this challenging disease and improving the lives of those affected.

Date :
  1. Date Completed 2022-01-03
  2. Date Revised 2022-01-03
Further Info :

Pubmed ID

34309665

DOI: Digital Object Identifier

PMC8314140

Related Literature

Article Analysis
・Side Effects of capecitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.